TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
SAN DIEGO - Gyre Therapeutics (NASDAQ:GYRE), a biotechnology company specializing in organ fibrosis treatments with a market capitalization of approximately $988 million, announced today the initiation of a public offering of its common stock. According to InvestingPro data, the company maintains strong financial health with a 96% gross profit margin and annual revenue of about $101 million. The company also intends to provide underwriters a 30-day option to purchase additional shares at the public offering price, after underwriting discounts and commissions.
The offering’s completion, size, and terms are not guaranteed and will depend on market conditions. Gyre will be the sole seller of the shares and plans to allocate the net proceeds toward its Phase 2 clinical trial of F351 for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis (MASH) in the U.S., alongside research and development, manufacturing, working capital, and general corporate purposes. InvestingPro analysis shows the company operates with a healthy balance sheet, maintaining a current ratio of 3.6 and minimal debt-to-equity ratio of 0.02, suggesting strong financial flexibility for its clinical development programs.
Jefferies LLC is leading the offering as the book-running manager, with H.C. Wainwright & Co. serving as the co-manager. The shares are being offered pursuant to an effective shelf registration statement, previously declared by the Securities and Exchange Commission (SEC) on November 22, 2024.
Interested investors can access the preliminary prospectus supplement and accompanying prospectus filed with the SEC, available on the SEC’s website. The documents provide comprehensive information about Gyre and the offering.
Gyre Therapeutics, headquartered in San Diego, California, is focused on the development and commercialization of its drug, Hydronidone, for treating liver fibrosis, including MASH, within the U.S. It also has a controlling interest in Gyre Pharmaceuticals in China, which is advancing a broad pipeline of therapies. Investors tracking GYRE’s progress can access additional insights through InvestingPro, which offers 8 more exclusive ProTips and detailed financial metrics to help evaluate the company’s investment potential ahead of its next earnings report on August 19, 2025.
This press release includes forward-looking statements, subject to substantial risks and uncertainties, and should not be considered a guarantee of future performance or events. The actual results and timing of events could differ materially from those projected in the forward-looking statements due to various risks, including market conditions, clinical trial outcomes, regulatory processes, and capital resource sufficiency.
The information in this article is based on a press release statement from Gyre Therapeutics.
In other recent news, Gyre Therapeutics reported fourth-quarter revenue of $27.87 million and provided a full-year 2025 revenue guidance that did not meet analyst expectations. The company anticipates 2025 revenue between $118 million to $128 million, which reflects growth over 2024 but remains below the $135.7 million analysts had projected. Gyre plans to launch two new products in 2025: nintedanib for idiopathic pulmonary fibrosis and avatrombopag for chronic liver disease-associated thrombocytopenia. These products are expected to be introduced in China to enhance their existing ETUARY (pirfenidone) portfolio. Additionally, Gyre Therapeutics has received approval from China’s National Medical Products Administration to start a clinical trial for pirfenidone, targeting radiation-induced lung injury and checkpoint inhibitor pneumonitis. In another development, the company has published the protocol for its Phase 3 trial on hydronidone, aimed at treating liver fibrosis in chronic hepatitis B patients. The trial, which completed patient enrollment in October 2024, will assess the drug’s efficacy over a 52-week period. These recent developments highlight Gyre’s ongoing efforts to expand its treatment offerings for organ fibrosis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.